Table 1.
Cox proportional hazard analysis for overall survival in the JGOG-TR2 cohort.
| Univariate | Multivariate (n = 253) | Multivariate (n = 156) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Covariates | N = 274 | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Age | <62 | 137 | |||||||||
| >=62 | 137 | 1.52 | (0.95–2.43) | 0.084 | 1.28 | (0.72–2.25) | 0.4 | 0.95 | (0.48–1.87) | 0.89 | |
| Performance status | 0 | 202 | |||||||||
| >= 1 | 64 | 2.05 | (1.23–3.43) | 0.0063 | 1.68 | (0.94–3.00) | 0.083 | 1.07 | (0.51–2.25) | 0.85 | |
| Surgery | PDS | 125 | |||||||||
| IDS | 120 | 2.34 | (1.32–4.14) | 0.0036 | 3.05 | (1.51–6.17) | 0.0019 | 4.2 | (1.67–10.59) | 0.0023 | |
| NDS | 29 | 7.52 | (3.78–14.98) | 9.3 × 10−9 | 3.17 | (1.28–7.89) | 0.013 | 8.69 | (2.82–26.74) | 1.6 × 10−4 | |
| Residual tumour | R0 | 162 | |||||||||
| R1 | 44 | 1.73 | (0.91–3.30) | 0.093 | 1.47 | (0.76–2.86) | 0.25 | 1.53 | (0.73–3.20) | 0.26 | |
| R2 | 68 | 3.26 | (1.94–5.50) | 9.0 × 10−6 | 3.36 | (1.58–7.10) | 0.0016 | 4.26 | (1.64–11.03) | 0.0028 | |
| BRCA1 methylation | No | 219 | |||||||||
| Yes | 46 | 1.02 | (0.56–1.86) | 0.96 | 2.93 | (1.37–6.27) | 0.0055 | 2.86 | (1.08–7.60) | 0.035 | |
| HRD score (median) | Low | 132 | |||||||||
| High | 133 | 0.58 | (0.36–0.94) | 0.028 | 0.64 | (0.36–1.13) | 0.12 | ||||
| HRD score (ROC curve) | Low | 120 | |||||||||
| High | 145 | 0.61 | (0.38–0.98) | 0.039 | 1.54 | (0.63–3.75) | 0.34 | ||||
| HRDness signature | Low | 135 | |||||||||
| High | 136 | 0.48 | (0.30–0.79) | 0.0039 | 0.4 | (0.21–0.76) | 0.0055 | ||||
| HRDness prediction | Negative | 76 | |||||||||
| Positive | 93 | 0.4 | (0.23–0.70) | 0.0012 | 0.16 | (0.06–0.42) | 2.2 × 10−4 | ||||
| ConsensusOV | IMR | 71 | |||||||||
| MES | 77 | 1.55 | (0.83–2.90) | 0.17 | 1.57 | (0.78–3.14) | 0.2 | 1.85 | (0.73–4.65) | 0.19 | |
| DIF | 80 | 0.79 | (0.39–1.62) | 0.53 | 1.57 | (0.69–3.56) | 0.28 | 1.59 | (0.59–4.25) | 0.36 | |
| PRO | 43 | 1.52 | (0.73–3.16) | 0.26 | 0.96 | (0.41–2.24) | 0.93 | 0.91 | (0.32–2.58) | 0.86 | |
HR hazard ratio, 95% CI 95% confidence interval, PDS primary debulking surgery, IDS interval debulking surgery, NDS non-debulking surgery, R0 no residual tumour, R1 residual tumour under 1 cm in diameter, R2 residual tumour more than 1 cm in diameter, IMR immunoreactive, MES mesenchymal, DIF differentiated, PRO proliferative.